LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin by inhibiting miR-143 expression
- PMID: 33577022
- DOI: 10.26355/eurrev_202101_24629
LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin by inhibiting miR-143 expression
Abstract
Objective: The aim of this study was to explore the effect of long non-coding ribonucleic acid (lncRNA) FOXD2-adjacent opposite strand RNA 1 (FOXD2-AS1) on the sensitivity of osteosarcoma cells to cisplatin and its possible underlying mechanism. Our findings might help to provide a certain reference for clinically preventing the drug resistance of osteosarcoma cells.
Materials and methods: Cisplatin with a certain concentration gradient was used to induce the stable acquired resistance of human osteosarcoma U2-OS cell line. Subsequently, the expression level of lncRNA FOXD2-AS1 was determined in osteosarcoma cells in non-resistance group (Control group) and Cisplatin-resistance group (Cisplatin-RES group), respectively. Next, the cell line with stable lncRNA FOXD2-AS1 knockdown was constructed in Cisplatin-RES group using small interfering RNA (siRNA). The effects of stable knockdown of lncRNA FOXD2-AS1 on the proliferation of human osteosarcoma cells and the half-maximal inhibitory concentration (IC50) of cisplatin were detected by Cell Counting Kit-8 (CCK-8) assay. 5-ethynyl-2'-deoxyuridine (EdU) staining was performed to measure deoxyribonucleic acid (DNA) replication level in each group of cells. The protein expression levels of apoptosis-associated genes B-cell lymphoma 2 (Bcl-2) and Bcl-2 associated X protein (Bax) in each group of cells were measured via Western blotting. The migration and invasion abilities of cells in each group were determined using wound-healing assay and transwell assay. In addition, the expression of micro RNA (miR)-143 in each group of cells was detected via Reverse Transcription-Polymerase Chain Reaction (RT-PCR).
Results: Compared with Control group, the expression level of lncRNA FOXD2-AS1 rose significantly in cells in Cisplatin-RES group (p<0.05). Knockdown of FOXD2-AS1 evidently decreased the IC50 of cisplatin in human osteosarcoma cells (p<0.05). According to EdU staining results, the knockdown of FOXD2-AS1 distinctly inhibited the proliferation of osteosarcoma cells (p<0.05). Western blotting results demonstrated that the knockdown of FOXD2-AS1 remarkably upregulated the expression of pro-apoptotic protein Bax and repressed that of anti-apoptotic protein Bcl-2 in drug-resistant human osteosarcoma cells (p<0.05). Moreover, the knockdown of FOXD2-AS1 significantly weakened the migration and invasion abilities of drug-resistant human osteosarcoma cells (p<0.05). Finally, it was found that the expression level of miR-143 was distinctly elevated in drug-resistant human osteosarcoma cells after knockdown of FOXD2-AS1 (p<0.05).
Conclusions: LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin, promotes their apoptosis and weakens their invasion and migration abilities. The possible underlying mechanism may be related to the inhibition of miR-143 expression by lncRNA FOXD2-AS1 in drug-resistant cell lines.
Similar articles
-
Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142.Med Sci Monit. 2020 Mar 10;26:e921594. doi: 10.12659/MSM.921594. Med Sci Monit. 2020. PMID: 32155139 Free PMC article.
-
LncRNA NORAD targets miR-410-3p to regulate drug resistance sensitivity of osteosarcoma.Cell Mol Biol (Noisy-le-grand). 2020 Jun 5;66(3):143-148. Cell Mol Biol (Noisy-le-grand). 2020. PMID: 32538761
-
Silencing lncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p/CPEB4 axis.Aging (Albany NY). 2019 Nov 26;11(22):10266-10283. doi: 10.18632/aging.102455. Epub 2019 Nov 26. Aging (Albany NY). 2019. PMID: 31770107 Free PMC article.
-
A review on the role of FOXD2-AS1 in human disorders.Pathol Res Pract. 2024 Feb;254:155101. doi: 10.1016/j.prp.2024.155101. Epub 2024 Jan 9. Pathol Res Pract. 2024. PMID: 38211387 Review.
-
The critical roles of lncRNAs in the development of osteosarcoma.Biomed Pharmacother. 2021 Mar;135:111217. doi: 10.1016/j.biopha.2021.111217. Epub 2021 Feb 1. Biomed Pharmacother. 2021. PMID: 33433358 Review.
Cited by
-
Emerging roles of long non-coding RNAs in osteosarcoma.Front Mol Biosci. 2024 Mar 7;11:1327459. doi: 10.3389/fmolb.2024.1327459. eCollection 2024. Front Mol Biosci. 2024. PMID: 38516191 Free PMC article. Review.
-
Identification of pyroptosis-related genes and long non-coding RNAs signatures in osteosarcoma.Cancer Cell Int. 2022 Oct 16;22(1):322. doi: 10.1186/s12935-022-02729-1. Cancer Cell Int. 2022. PMID: 36244998 Free PMC article.
-
Navigating the genomic instability mine field of osteosarcoma to better understand implications of non-coding RNAs.Biocell. 2022 Jun 13;46(10):2177-2193. doi: 10.32604/biocell.2022.020141. Biocell. 2022. PMID: 35755302 Free PMC article.
-
Non-coding RNAs in drug and radiation resistance of bone and soft-tissue sarcoma: a systematic review.Elife. 2022 Nov 3;11:e79655. doi: 10.7554/eLife.79655. Elife. 2022. PMID: 36326232 Free PMC article.
-
Lnc-PHF3-3 aggravates the chemoresistance of osteosarcoma cells to doxorubicin via the miR-142-3p/HMGB1 axis.Transl Oncol. 2025 Mar;53:102328. doi: 10.1016/j.tranon.2025.102328. Epub 2025 Feb 18. Transl Oncol. 2025. PMID: 39970626 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials